|1.||Beckman, Robert A: 4 articles (10/2015 - 11/2013)|
|2.||Greenberg, Jonathan: 3 articles (10/2015 - 12/2013)|
|3.||Wang, Qiang: 3 articles (10/2015 - 12/2013)|
|4.||Forero-Torres, Andres: 3 articles (06/2015 - 02/2010)|
|5.||Cheng, Ann-Lii: 2 articles (10/2015 - 03/2012)|
|6.||He, Aiwu Ruth: 2 articles (10/2015 - 12/2013)|
|7.||Scott, Andrew M: 2 articles (08/2015 - 11/2013)|
|8.||Brechbiel, Martin W: 2 articles (08/2015 - 11/2013)|
|9.||O'Keefe, Graeme J: 2 articles (08/2015 - 11/2013)|
|10.||von Roemeling, Reinhard: 2 articles (12/2013 - 11/2013)|
|1.||Hepatocellular Carcinoma (Hepatoma)
03/15/2012 - "Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3."
10/01/2015 - "Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study."
10/01/2015 - "In this phase II study, safety and tolerability of the combination of tigatuzumab and sorafenib was evaluated in patients with advanced hepatocellular carcinoma. "
10/01/2015 - "Tigatuzumab combined with sorafenib vs. sorafenib alone in adults with advanced hepatocellular carcinoma did not meet its primary efficacy end point, although tigatuzumab plus sorafenib is well tolerated in hepatocellular carcinoma."
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
12/01/2013 - "This phase 2 trial evaluated the efficacy of tigatuzumab combined with gemcitabine in 62 chemotherapy-naive patients with histologically or cytologically confirmed unresectable or metastatic pancreatic cancer. "
12/01/2013 - "Tigatuzumab combined with gemcitabine was well tolerated and may be clinically active for the treatment of chemotherapy-naive patients with unresectable or metastatic pancreatic cancer."
12/01/2013 - "Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer."
06/15/2015 - "Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5(+) human tumor cells without crosslinking. "
12/01/2013 - "Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. "
03/15/2012 - "Moreover, in vivo the combination of tigatuzumab and dovitinib inhibited Huh-7 xenograft tumor growth. "
12/01/2013 - "Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. "
11/01/2013 - "CS-1008 (tigatuzumab; phase I/II), an antihuman death receptor 5 (DR5) agonist, induces apoptosis and has cytotoxic activity against human cancer cell lines. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
08/20/2015 - "CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer (mCRC). "
|2.||sorafenib (BAY 43-9006)
|3.||TNF-Related Apoptosis-Inducing Ligand Receptors
|7.||Immunoglobulin G (IgG)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)